Homologous Recombination Repair Gene Mutation Characterization by Liquid Biopsy: A Phase II Trial of Olaparib and Abiraterone in Metastatic Castrate-Resistant Prostate Cancer

SIMPLE SUMMARY: Mutations in homologous recombination repair (HRR) genes are frequent in advanced prostate cancer and tumours harbouring these mutations have known sensitivity to PARP inhibitors, such as olaparib. In the randomized double-blind Phase II study (NCT01972218), olaparib and abiraterone...

Descripción completa

Detalles Bibliográficos
Autores principales: Carr, T. Hedley, Adelman, Carrie, Barnicle, Alan, Kozarewa, Iwanka, Luke, Sally, Lai, Zhongwu, Hollis, Sally, Dougherty, Brian, Harrington, Elizabeth A., Kang, Jinyu, Saad, Fred, Sala, Nuria, Thiery-Vuillemin, Antoine, Clarke, Noel W., Hodgson, Darren, Barrett, J. Carl
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8616430/
https://www.ncbi.nlm.nih.gov/pubmed/34830984
http://dx.doi.org/10.3390/cancers13225830

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8616430/
https://www.ncbi.nlm.nih.gov/pubmed/34830984
http://dx.doi.org/10.3390/cancers13225830

Ejemplares similares